Skip to main content
. 2016 May 6;95(18):e3519. doi: 10.1097/MD.0000000000003519

FIGURE 4.

FIGURE 4

Kaplan–Meier estimates of RFS and OS in the non-CN-AML patients. The relapse-free survival [RFS] (A) and overall survival [OS] (B) of DNMT3A R882 mutations were shown in noncytogenetically normal (CN)-AML patients, including 25 with DNMT3A R882 mutations and 205 without R882 mutations (n = 230). The median survival of RFS: DNMT3A R882 mutations vs without R882 mutations = 8.8 vs 24.2, P = 0.006; and the median survival of OS: DNMT3A R882 mutations vs without R882 mutations = 12.3 vs 32.5, P = 0.0038.